Across TCGA pan-cancer cohorts, RBMY1A3P Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RBMY1A3P data layer compared with 10 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher RBMY1A3P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RBMY1A3P expression acts as an unfavorable survival marker.

LUSC and LUAD are the cancer types where RBMY1A3P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.133	0.776	<.001	24	view →
LUAD	OS	Median	II,III,IV	0.079	0.709	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RBMY1A3P tumor-vs-normal RNA expression · all RBMY1A3P data types